Ask AI
PI3K/AKT Inhibitors in mBC

CE / CME

PI3K/AKT Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer (mBC)

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

European Learners: 0.25 hours EBAC® effective education time

Released: October 24, 2025

Expiration: April 23, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following PI3K/AKT inhibitors is indicated in patients for all PIK3CA, AKT, and PTEN pathway alterations?

2.

Which of the following approved PI3K inhibitors also promotes degradation of the PI3K protein?